Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570589 | 0.92 | TSHR (0.35) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL1104607 | 0.84 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL4122685 | 0.84 | TSHR (0.35) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL12313901 | 0.81 | TSHR (0.37) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL12972095 | 0.81 | TSHR (0.39) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL12988459 | 0.81 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL1104609 | 0.81 | ALDH1A1 (0.32) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL17612297 | 0.81 | SMN1; SMN2 (0.37) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL15440624 | 0.79 | TSHR (0.35) | SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL15672320 | 0.79 | TSHR (0.35) | SMN1; SMN2TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070059607-A1 | Cyclic carbonate-modified organosilicon compound, non-aqueous electrolytic solution comprising same, secondary battery, and capacitor | SHIN-ESTU CHEMICAL CO., LTD. | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059607-A1 | Cyclic carbonate-modified organosilicon compound, non-aqueous electrolytic solution comprising same, secondary battery, and capacitor | CA12, CA1, PIEZO1 | SMN1; SMN2 2676/4885TSHR 4296/4885ALDH1A1 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.